ArticleJACC. Advances2026
The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic Heterogeneity of Obesity and Outcome-Specific Effects of GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome.JACC. Advances · 2026Article
- Reply: Metabolic Heterogeneity of Obesity and Outcome-Specific Effects of GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome.JACC. Advances · 2026Article
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has long been acknowledged that the risk of cardiovascular disease is impacted by a complex interplay between the heart and kidneys. The relationship among cardiovascular disease, chronic kidney disease, and metabolic diseases, including obesity and diabetes, has now been recognized as "cardiovascular-kidney-metabolic (CKM) syndrome". Specialist clinicians have historically approached these disorders as separate diseases, with individual treatment plans specific to dysfunction of each organ system. However, the recognition of a syndrome of CKM dysfunction and the advent of therapeutic agents with pleiomorphic effects across multiple organ systems, such as glucagon-like peptide-1 receptor agonists, which target various components of CKM, may encourage clinicians to take a more holistic approach to treatment of people with CKM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.